Could a fibrosis drug help women with adenomyosis get pregnant?

NCT ID NCT07162961

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether adding nintedanib, a drug that reduces scarring, to standard progesterone therapy can improve live birth rates in infertile women with adenomyosis. About 328 women aged 20-38 with frozen embryos will take either nintedanib plus progesterone or progesterone alone for three months before embryo transfer. The goal is to see if the combination leads to more successful pregnancies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

nintedanib (an antifibrotic drug) plus progesterone

What this could lead to

If it works, this could offer a new treatment to improve pregnancy chances for women with adenomyosis who have frozen embryos.

What could go wrong

This is an early Phase 3 trial with no results yet. The drug may not improve live birth rates, and side effects from nintedanib are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOMYOSIS OF UTERUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenomyosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.